Prosight Management’s Palvella Therapeutics PVLA Stock Holding History

Prosight Management’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$623K	Buy	+5,000	New	+$522K	0.1%	43
2019 Q1	–	Sell	-4,161	Closed	-$885K	–	45
2018 Q4	$885K	Sell	4,161 -16,613	-80%	-$5.15M	0.46%	32
2018 Q3	$9.31M	Buy	20,774 +3,774	+22%	+$1.64M	5.19%	6
2018 Q2	$6.89M	Buy	17,000 +9,953	+141%	+$4.74M	5.05%	5
2018 Q1	$3.85M	Buy	+7,047	New	+$4.36M	2.41%	16

Other funds holding PVLA

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Prosight Management's PVLA Position: Q1 2026 in Review

Prosight Management opened a new position in Palvella Therapeutics (PVLA) in Q1 2026: 5,000 shares worth $623K. The stake represents 0.1% of the portfolio and ranks #43 among its holdings. This is a return to the name: Prosight Management previously reported a position in PVLA as recently as Q4 2018.

Prosight Management first reported a position in PVLA in Q1 2018 and has held it in 5 quarters since. The position peaked at $9.31M in Q3 2018. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

Prosight Management held 5,000 shares of Palvella Therapeutics worth $623K as of Q1 2026.
Palvella Therapeutics was a new Prosight Management position in Q1 2026.
Palvella Therapeutics made up 0.1% of Prosight Management's portfolio in Q1 2026, its #43 holding.
Prosight Management first reported a position in Palvella Therapeutics in Q1 2018 and has held it in 5 quarters since.
Prosight Management's Palvella Therapeutics position peaked at $9.31M in Q3 2018.
180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Prosight Management's 13F filing for Q1 2026, filed 15 May 2026.